{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper boundary were not estimated due to the limited number of participants with events.","groupId":"OG000","lowerLimit":"6.55","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Duration of response (DR) is defined as the time from the first response to progressive disease (PD). See outcome #4 for a PD definition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine in escalating doses of 50, 70 or 90 mg/m\\^2 as combination therapy with bortezomib at 1.0 mg/m\\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.","id":"OG000","title":"Bendamustine and Bortezomib - Overall"}],"paramType":"MEDIAN","populationDescription":"Participants who had a response","reportingStatus":"POSTED","timeFrame":"up to 8.5 months","title":"Kaplan-Meier Estimate for Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}